Stock · REGN · Healthcare
United States · Large Cap · listed since 1991 · Revenue 12 mo. $16.9B
Price as of 11/06/2026
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Original text from the data provider
Summary
60.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €3.7B (2025), it supports €40.7B. The remaining €45.8B of the market value assume it grows 10.6% a year for 10 years and not at all afterwards.
Required FCF growth per year
10.6%
no growth afterwards
Price to operating cash flow 20.7×, above its usual range.
Middle half of 20 quarters: 13.3× to 19.2×, median 17.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q2 → Q3 2026
3 more unchanged: FCF, 12 mo., Gross margin, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 14.41% | 11.52% | Rank 64 |
| Return on capital (Greenblatt) | 19.06% | 32.55% | Rank 24 |
| EBIT margin | 24.95% | 18.31% | Rank 71 |
| FCF margin | 28.45% | 14.12% | Rank 89 |
| Gross margin | 85.35% | 60.99% | Rank 95 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 0.99% | 8.04% | Rank 15 |
| Earnings growth, 3 years per year | 2.76% | 5.44% | Rank 42 |
| Earnings growth, 5 years per year | 6.33% | 7.00% | Rank 47 |
| Sustainable growth (ROE × retained earnings) | 6.26% | 3.66% | Rank 78 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.59% | 2.90% | Rank 76 |
| FCF yield | 4.23% | 3.63% | Rank 56 |
| EV/saleslower is better | 6.31 | 4.03 | Rank 32 |
| EV/EBITlower is better | 25.30 | 21.73 | Rank 41 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 30.20% | 8.66% | Rank 78 |
| Share price, 6 months | 26.99% | 24.27% | Rank 57 |
| Share price, 3 months | 20.43% | 15.42% | Rank 68 |
| Distance from 52-week high | −7.09% | −7.35% | Rank 51 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 0.40% | 0.30% | Rank 49 |
| Change in share countlower is better | −5.65% | 0.00% | Rank 95 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | 14.93% | 0.05% | Rank 96 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 77.07% | 48.40% | Rank 88 |
| Net debt/EBITDAlower is better | −1.01 | 1.11 | Rank 84 |
| Debt to equitylower is better | 0.09 | 0.48 | Rank 82 |
| Volatility, 1 yearlower is better | 33.99% | 31.42% | Rank 42 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt, $M |
|---|---|---|---|---|---|
| 2016 | 4.9 | 27.4% | $974.0M | 116M | −54.1 |
| 2017 | 5.9 | 35.4% | $1.0B | 116M | −109.3 |
| 2018 | 6.7 | 37.8% | $1.8B | 115M | −759.2 |
| 2019 | 7.9 | 28.1% | $2.0B | 115M | −903.9 |
| 2020 | 8.5 | 42.1% | $2.0B | 115M | 502.0 |
| 2021 | 16.1 | 55.7% | $6.5B | 112M | −185.9 |
| 2022 | 12.2 | 44.2% | $4.4B | 114M | −404.5 |
| 2023 | 13.1 | 30.9% | $3.7B | 114M | −27.1 |
| 2024 | 14.2 | 28.1% | $3.7B | 115M | 216.2 |
| 2025 | 14.3 | 25.0% | $4.1B | 109M | −412.2 |
4 of 7 StockScorer Score rules met · How the score is built
Regeneron Pharmaceuticals Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Regeneron Pharmaceuticals Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Regeneron Pharmaceuticals Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 21.8 | 30.0 |
| P/B ratio | 3.1 | 4.8 |
| Return on equity (ROE) | 14.4% | 11.5% |
| Equity ratio | 77.1% | 48.4% |
| Debt-to-equity (D/E) | 0.09 | 0.48 |
| Dividend yield | 0.4% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| REGN | Regeneron Pharmaceuticals Incthis page | |
| MRNA | Moderna Inc | Low0.9 |
| VRTX | Vertex Pharmaceuticals Inc | Medium5.5 |
| RVMD | Revolution Medicines Inc | locked |
| RPRX | Royalty Pharma Plc | locked |
| INCY | Incyte Corporation | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.